STENTYS : Appoints Medical Device Executive to its Board of Directors (10 April 2014)

STENTYS Appoints Medical Device Executive to its

Board of Directors

Dianne Blanco, CEO of Orteq, brings 20 years of medical technology management experience

PRINCETON, N.J. and PARIS -

April 10, 2014 - STENTYS (FR0010949404 - STNT), a medical

technology company commercializing the world's first and only Self-Apposing®stent to treat acute myocardial infarction (AMI), today announced that Dianne Blanco has been appointed as a

Director to replace the representative from Omnes Capital venture capital fund.

Since its founding in 2006, Ms. Blanco has been CEO of Orteq, a medical device company specializing in novel biodegradable polymers in devices for repair and tissue regeneration in damaged joints by sports medicine surgeons. She has more than twenty years of experience in the medical technology industry in key management positions on an international scale. Prior to joining Orteq, she was Head of Baxter Healthcare's Medication Delivery division for the EMEA region.

Ms. Blanco replaces Alexia Pérouse of Omnes Capital, which has supported the Company's development since

2009. Her appointment will be submitted to the next Shareholders' Meeting for approval.

GonzagueIssenmann,co-founderandChiefExecutiveOfficerofSTENTYS,said:"We are delighted to welcome Dianne Blanco onto STENTYS' Board of Directors. Her experience represents a considerable asset for our Company's strategic objectives and international development."

About the STENTYS Self-Apposing®Stent

The STENTYS Self-Apposing®Stent addresses the stent-sizing dilemma that cardiologists are confronted with when treating heart attack
patients or patients with atypical artery anato
y. Its flexible, self expanding design takes the shape of the patient's unique vessel anatomy
and apposes to the irregular contours of a blo d vessel, in particular after an AMI as the vessel dilates and the clot dissolves. It reduces the risk of malapposition and complications associated with conventional stents in this setting. The STENTYS Self-Apposing Stent has been marketed in Europe since receiving CE Mark in 2010. The STENTYS Sirolimus-eluting stent is expected to receive CE Mark in H2 2014.

About STENTYS

STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS's Self-Apposing®Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, S ENTYS stents demonstrated a very low one year mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents.

More information is available at www.stentys.com .

This press release contains forward looking statements about the Company's business. Such forward l oking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environm nt in which it will operate in the
future which may not be accurate. Such forward-looking statements involve known and unknown risks
hich may cause the Company's
actual results, performance or achievements t
differ materially from any future results, performance or achievements expressed or implied
by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company's products, market acceptance of the Company's products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary ri hts, uncertainties related to the U.S. FDA approval process, including with res ect to a pre-market approval for the Company's BMS, slow r than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in t e Section 4 "Risk Factors" of the Company's 2011 Registration Document (documentderéférence) filed with the AutoritédesMarchésFinanciersin France on August 27,
2013 under number R.13-040 as such section may be updated from time to time.

Page 1 sur 2

Tel.: +33 (0)1 44 53 99 42 stan.p@stentvs.com

STENlYS is listed on Comp. B of the NYSE Euronext Paris

ISIN: FR0010949404- Ticker: STNT

Financial Communication l Investor Relations

Dusan Oresansky l Pierre Laurent Tel.: +33 (0)144 7194 93 stentvs@newcap.fr

Charles Liles, Tel.: 781 235 3060

Christine Labaree or Hunter Marshall, Tel.: 650 339 7533 stentvs@macbiocom.com

EURONEXT.

Page 2 sur 2

distributed by